Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: HardToFind who wrote (10183)	5/7/2018 7:20:58 PM
From: HardToFind	Read Replies (1) \| Respond to of 12873

I'd ask what was wrong with the first valuation, but I already have about five ideas: Ms. Myers was not informed that NNVC had already paid for nine (9) drug indications that have gone nowhere so far, including the other herpes viruses using the same molecule. NNVC has already paid TheraCour for all of the research that went into this additional indication, plus a 30% markup. We don't know if, or for how much, we can produce this drug in commercial quantities. The company is running out of money, and cannot afford to license another indication prior to another equity raise. (Debt financing is out of the question because there is no income and in case of bankruptcy the meaningful assets fall to TC.) A 15% royalty on revenues would sink the company.

To: HardToFind who wrote (10183)	5/8/2018 10:03:31 AM
From: donpat	Respond to of 12873

Funny, but fun - I Googled "Myers Nanoviricides" and got this: investorshub.advfn.com Ah, those were the days ;-) Today's Myers? --The market size for anti-shingles drugs is currently estimated to be in the range of several billions of dollars, even after a new shingles vaccine, Shingrix® (GlaxoSmithKline) has become available, based on a recent report by Dr. Myers of BioEnsemble, LLC, pharma industry consultants, commissioned by the Company. The Company believes that the anti-VZV drug candidates are very likely to be effective for dermal topical treatment of HSV-1 cold sores, as well genital ulcers caused by HSV-2, in addition to shingles. If the same anti-VZV/shingles drug candidates also demonstrate efficacy against the HSV-1 and HSV-2 animal models, then we will be ready to go into IND applications and clinical stage for these indications as well in relatively short time frames of six months to a year, after the first IND filing, depending upon the availability of funding. We had previously demonstrated significant efficacy of an anti-HSV-1 nanoviricide in animal models using nanoviricides based on closely related ligands and polymer that were not yet optimized. Thus we have made significant and substantial progress in the reporting quarter towards the goal of filing our first IND application, and we continue to build on this progress. The Company is continuing the process for licensing of the shingles indication from TheraCour Pharma, Inc.. To this end, the Company has reviewed the initial valuation report submitted by Dr. Myers of BioEnsemble, LLC. Thereafter, we have asked that further modeling and analysis be performed incorporating additional assumptions that reflect our situation more closely than in the model that was presented. Thereafter, we anticipate license agreements will be drafted and the terms and conditions will be negotiated. TheraCour has in the past not denied any licenses for any virus programs that we initiated. We have retained counsel to prepare and negotiate the new license agreement on our behalf. If we cannot come to an agreement with TheraCour for the shingles license, we will continue and accelerate our work on the HSV-1 (cold sores) and HSV-2 (genital ulcers) indications, which we believe will be using essentially the same or closely related dermal topical drug candidates as in development under the VZV banner at present in the HerpeCide™ program. The Company already has licenses from TheraCour for these indications. Additionally, the Company reported that Dr. Eugene Seymour, MD, MPH, the Company's co-founder and CEO, has resigned from his position as CEO as well as a Director of the Company to allow a successor with a pharmaceutical background in shepherding drugs through the process to FDA approval, to be appointed to serve in this capacity. Upon entry into severance agreement Dr. Seymour will assume the role of Chief Executive Officer Emeritus. The Board of Directors commenced a search for a permanent replacement for Dr. Seymour, which is ongoing. Pending the appointment of a permanent Chief Executive Officer, the Board of Directors appointed Dr. Anil Diwan, the Company's President, as Interim Chief Executive Officer.-- https://www.prnewswire.com/news-releases/nanoviricides-files-quarterly-report-for-period-ending-december-31-2017-300601706.html Looks like Glaxo, shingles, Theracour and money figure in Myers' activities. Great training ground for a CEO! And NNVC is looking for a new CEO to get through the FDA hurdles. Is Myers involved in the CEO hunt? Not as far as I know. It looks to me that, generally speaking, NNVC is on the nub of greatness and wants to get it right.